Alpha 2.0
Login Register
» Articles » PMID: 36742077

Corrigendum: Immune Checkpoint Inhibitor Therapy Increases Systemic SDF-1, Cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, Galectine-3, and NLRP3-MyD88-chemokine Pathways

Overview
Journal Front Cardiovasc Med
Specialty Cardiology & Vascular Diseases
Date 2023 Feb 6
PMID 36742077
Authors
Vincenzo Quagliariello
Margherita Passariello
Annabella Di Mauro
Ciro Cipullo
Andrea Paccone
Antonio Barbieri
Giuseppe Palma
Antonio Luciano
Simona Buccolo
Irma Bisceglia
Maria Laura Canale
Giuseppina Gallucci
Alessandro Inno
Claudia De Lorenzo
Nicola Maurea
Affiliations
Soon will be listed here.
Abstract

[This corrects the article DOI: 10.3389/fcvm.2022.930797.].

Citing Articles

Sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents ejection fraction reduction, reduces myocardial and renal NF-κB expression and systemic pro-inflammatory biomarkers in models of short-term doxorubicin cardiotoxicity.

Quagliariello V, Canale M, Bisceglia I, Iovine M, Paccone A, Maurea C Front Cardiovasc Med. 2024; 11:1289663.

PMID: 38818214 PMC: 11138344. DOI: 10.3389/fcvm.2024.1289663.